Ryan Livingston

Patients experienced significantly fewer thromboembolic complications when treated with ICE, indicating its comparatively noninferior safety and efficacy.

The phase 3 ZENITH trial showed sotatercept’s superiority over placebo in reducing morbidity and mortality outcomes in adults with WHO FC III or IV PAH.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Results from the phase 3 trial show consistent reductions in annualized bleeding rate after 12 months of once-weekly treatment.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

The investigative therapy for treatment-resistant hypertension resulted in a substantial reduction in ambulatory 24-hour average systolic blood pressure versus placebo.

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

Lifelong reliance on insulin, constant glucose monitoring, and management of hypo- and hyperglycemia require substantial lifestyle changes.

Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.

Amgen announced that evolocumab reduced the risk of MACEs such as heart attack and stroke in patients without any prior history of these events.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

A recent publication from the HFSA highlights obesity, chronic kidney disease, diabetes mellitus, and hypertension as major driving forces.

Biolinq Shine aims to provide continuous glucose monitoring, as well as sleep and activity data, without requiring injections.